By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Bridge to New Markets.

Potential biomarker discovered for brain tumors in children

researcher in lab © Medical University of Vienna/Houdek

This was shown by a study conducted at the Medical University of Vienna (MedUni Vienna) and Vienna General Hospital within the framework of the Comprehensive Cancer Center (CCC) and in collaboration with the German Cancer Research Center in Heidelberg.

The new study by Johannes Gojo, junior doctor and researcher at the Department of Pediatrics and Adolescent Medicine of MedUni Vienna and Vienna General Hospital and member of the CCC, investigated whether the enzyme telomerase could be used as a biomarker for ependymomas. Gojo states: "We were able to show that telomerase was primarily reactivated in tumors that exhibit a particularly aggressive course. This means that the tumor recurred despite surgical removal and subsequent radiotherapy and chemotherapy." The scientists suspect that this will enable them to identify patients who would benefit from more intensive treatment. Conversely, patients with less aggressive tumors could be spared chemotherapy. This would mean a huge improvement in the quality of life for those affected. "Together with other parameters, the presence of telomerase could be a big help in deciding on the course of treatment. It therefore represents a highly promising biomarker.” The study was published in the leading scientific journal Nero-Oncology.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • ABA's Open Day 2021: Austria - Your ICT and Innovation Hub in the Heart of Europe

    11 March 2021/ 09.00am + 05.00 pm, Online Conference

  • Meet us @ International Machinery Forum 2021 - The Factory of Tomorrow

    11.03 - 12.03 2021, Online Conference

Austria Map

Find the perfect location for your company

Investments in research and innovation are the basis of success for our company. The business location of Austria offers us an attractive environment of development funding, non-university research facilities and access to optimally trained engineers and university progrlammes“, states Markus Staeblein, Managing Director of NXP Austria GmbH.

NXP Semiconductors Austria GmbH

Logo: NXP Semiconductors Austria GmbH
More testimonials

news from the business location Austria

OMV and Kommunalkredit invest in the production of green hydrogen

The Austrian oil and gas company OMV and Kommunalkredit Austria AG (Kommunalkredit) have announced a joint investment in the construction of Austria’s largest electrolysis plant to be located in the OMV Schwechat Refinery.

Evotec SE

Evotec is an active substance research company which rapidly presses ahead with innovative product approaches on the basis of development partnerships with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists.

More news All blog posts